Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma
2018-001627-39Phase 2Completed
- Sponsor
- Incyte
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab in Merkel cell carcinoma (MCC), sponsored by Incyte. Primary endpoint: Objective Response Rate (ORR) in chemotherapy-naive population. Started Nov 2018; status: completed.
02
Drugs
retifanlimab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2018-001627-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001627-39.